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even in unperturbed cell cycles (Kaneko et al., 1999; Zhao et
al., 2002; Sørensen et al., 2003), and although it is further acti-
vated in response to DNA damage or stalled replication, this
may not require Chk1 dimerization or autophosphorylation
(Figure 1B). The original concept of rather strict dependency of
Chk1 on ATR, and Chk2 on ATM, has recently been softened by
reports of various “crosstalks” among these kinases (Figure 1),
exemplified by phosphorylation/activation of Chk1 by ATM in
response to ionizing radiation (Gatei et al., 2003; Sørensen et
al., 2003), the identification of a novel checkpoint cascade sig-
naling via ATM-Chk1 to Tlk kinases and thereby likely to chro-
matin remodeling in response to various stresses (Groth et al.,
2003), reports of ATM-independent activation of Chk2 (Hirao et
al., 2002), as well as by the ATX kinase whose links to Chk1 and
Chk2 remain to be elucidated.
An exciting recent development in this field has been the
identification of a group of large, BRCT domain-containing pro-
teins including 53BP1, BRCA1, and MDC1 as “mediators” of
checkpoint responses (Wang et al., 2000, 2002; DiTullio et al.,
2002; Fernandez-Capetillo et al., 2002; Yarden et al., 2002;
Goldberg et al., 2003; Stewart et al., 2003; Lou et al., 2003; Lee
et al., 2000). The emerging role of these proteins is to modulate
diverse checkpoint events, including activation of Chk1 and
Chk2, and promotion of other ATM-mediated phosphorylation
events through protein-protein interactions involved in “match-
maker” and/or recruitment functions (Figure 1). While BRCA1 is
an established tumor suppressor (Scully and Livingston, 2000)
and 53BP1-deficient mice are tumor prone (Ward et al., 2003), it
remains to be seen whether 53BP1 and MDC1 are also target-
ed in human cancer.
The fact that Chk1 and Chk2 perform partly redundant roles
becomes evident from the spectra of their known substrates
(Bartek et al., 2001; McGowan, 2002), most of which are shared
by both kinases (Figure 2). Through targeting these down-
stream effector proteins that also include recent additions such
as the Tlk kinases (Groth et al., 2003), the PML protein (Yang et
al., 2002), the PLK3 kinase (Xie et al., 2002), or the E2F1 tran-
scription factor (Stevens et al., 2003), Chk1 and Chk2 regulate
fundamental cellular functions such as DNA replication and cell
cycle progression, chromatin restructuring, and apoptosis
(Figure 2). Consistent with the fact that some substrates of
Chk2 such as Cdc25A or p53 are soluble, mobile proteins, and
with the need to rapidly spread the checkpoint signal from local-
ized sites of DNA damage to such targets, live-cell imaging of
Genomic instability, checkpoint defects, and cancer
The multistep evolution of cancer reflects accumulation of
genetic changes that lead to transformation of normal cells to
cancer cells and development from normal tissues into benign,
and eventually invasive, malignant tumors. The accumulating
alterations of tumor suppressor genes and protooncogenes
facilitate tumorigenesis and, through selection of genetic vari-
ants, such alterations can also affect responses to radiotherapy
and chemotherapy. Recent evidence implicates DNA repair and
the so-called genome integrity checkpoints as the culprits
whose defects are largely responsible for the enhanced genetic
instability of cancer cells (Hoeijmakers, 2001; Bartek and
Lukas, 2001; Khanna and Jackson, 2001).The checkpoint path-
ways are phyllogenetically conserved signaling cascades acti-
vated in response to DNA damage or errors in cell cycle events
such as DNA replication or chromosome segregation (Zhou and
Elledge, 2000). The activated checkpoints delay cell cycle pro-
gression to facilitate DNA repair, and they can also eliminate the
hazardous damaged cells through induction of cell death, there-
by protecting the organism against cancer. The checkpoint net-
work must not only sense the damage, but also promptly spread
such signals to reach the downstream cellular effector proteins.
In this review, we highlight the roles of mammalian kinases
Chk1 and Chk2 (the latter also known as Cds1 or CHEK2), two
critical messengers of the genome integrity checkpoints, and
particularly their involvement in the evolution of human cancer.
Chk1 and Chk2 in checkpoint signaling
Chk1 and Chk2 are structurally unrelated yet functionally over-
lapping serine/threonine kinases activated in response to
diverse genotoxic insults (reviewed in Bartek et al., 2001;
McGowan 2002). The key mission of Chk1 and Chk2 is to relay
the checkpoint signals from the proximal checkpoint kinases of
the phosphatidylinositol 3-kinase family, particularly ATM and
ATR, and likely also the newly identified ATX (Abraham, 2001;
Shiloh, 2003; Kastan and Lim, 2000; and R. Abraham, personal
communication), which phosphorylate and activate Chk1 and/or
Chk2 (Figure 1). Chk2 is a stable protein expressed throughout
the cell cycle (Lukas et al., 2001), it appears to be largely inac-
tive in the absence of DNA damage, it is activated mainly by
ATM in response to double-strand DNA breaks (DSBs), and its
activation involves dimerization and autophosphorylation
(Figure 1A). In contrast, the labile Chk1 protein is largely
restricted to S and G2 phases (Lukas et al., 2001), it is active
CANCER CELL : MAY 2003 · VOL. 3 · COPYRIGHT © 2003 CELL PRESS 421
R E V I E W
Chk1 and Chk2 kinases in checkpoint control and cancer
Jiri Bartek* and Jiri Lukas
Department of Cell Cycle and Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, 
DK-2100 Copenhagen, Denmark
*Correspondence: bartek@biobase.dk
Accumulation of mutations and chromosomal aberrations is one of the hallmarks of cancer cells.This enhanced genetic insta-
bility is fueled by defects in the genome maintenance mechanisms including DNA repair and cell cycle checkpoint pathways.
Here, we discuss the emerging roles of the mammalian Chk1 and Chk2 kinases as key signal transducers within the complex
network of genome integrity checkpoints, as candidate tumor suppressors disrupted in sporadic as well as some hereditary
malignancies and as potential targets of new anticancer therapies.
422 CANCER CELL : MAY 2003
Chk2 in human cells exposed to subnuclear DNA damage
revealed immediate redistribution of the activated Chk2
throughout the nucleus. Thus, the repeatedly observed “foci” of
activated Chk2 represent an unfortunate artifact attributable to
crossreactive antibodies against the Thr68-phosphorylated
Chk2, and the new data (Lukas et al., 2003) document the rapid
mobility and the lack of accumulation at sites of DNA damage,
supporting the role of Chk2 as the checkpoint signal spreader.
The lack of nuclear foci formation after DNA damage distin-
guishes Chk2 from many other DNA damage checkpoint pro-
teins, yet it is shared with Chk1 (C. Lukas, personal
communication), again pointing to analogous functions of these
two checkpoint transducers.
Lessons learned from Chk1 and Chk2 knockout and
knockdown models
Despite their overlapping roles in checkpoint signaling, the bio-
logical requirements for Chk1 and Chk2 function are strikingly
different, as Chk1 (Liu et al., 2000; Takai et al., 2000) but not
Chk2 (Hirao et al., 2002;Takai et al., 2002) is essential for mam-
malian development and viability. The early embryonic lethality
of the Chk1-deficient mice and the acute lethality of Chk1-defi-
cient embryonic cells (Liu et al., 2000; Takai et al., 2000)
allowed only limited analysis of the consequences of Chk1
absence for checkpoint functions, yet these studies implicated
Chk1 in the G2/M DNA damage response and the S-M check-
point in response to incomplete DNA replication. In contrast,
complete deficiency of Chk1 in avian somatic DT-40 lymphoma
cells (Zachos et al., 2003) can be tolerated and does not affect
cell division, while it abolished DNA damage-induced G2 arrest,
undermined replication checkpoint responses, and sensitized
cells to killing upon perturbations of DNA structure or metabo-
lism. RNAi-mediated knockdown of Chk1 in human cells
revealed an essential role of this kinase in the control of Cdc25A
protein turnover and thereby in both normal S phase and the
intra-S phase DNA damage checkpoint (Zhao et al., 2002;
Sørensen et al., 2003) and confirmed the requirement for Chk1
in the G2/M checkpoint in response to ionizing radiation (Gatei
et al., 2003) and some DNA-damaging drugs (Xiao et al., 2003).
The Chk2-deficient mice are viable, fertile, and do not show
a tumor-prone phenotype except when exposed to carcinogens,
or possibly later in their lives if left unperturbed (Takai et al.,
2002; Hirao et al., 2002). Although there are some discrepan-
cies in the results of the different studies with Chk2-deficient
mice and cells derived from them, the observed phenotype was
dominated by increased resistance of the Chk2−/− mice to ioniz-
ing radiation, and cellular defects in p53 function, some check-
point responses, and especially in apoptosis (Takai et al., 2002;
Hirao et al., 2002; Hirao et al., 2000; Jack et al., 2002). Chk2-
deficient HCT-15 human colon carcinoma cells have also been
used to study Chk2 function, particularly in the intra-S phase
checkpoint in response to DSBs (Falck et al., 2001a, 2001b,
2002), a role recently confirmed by S phase checkpoint mal-
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Figure 1. Upstream regulation of Chk1 and Chk2 under genotoxic stress
A: Ionizing radiation, telomere erosion, and radiomimetic drugs generate
DNA double-strand breaks (DSB) and activate the ATM kinase (Shiloh,
2003). ATM phosphorylates the N-terminal regulatory domain of Chk2,
exemplified here by the most prominent, threonine 68 phosphorylation
(Bartek et al., 2001). This in turn promotes homodimerization and intermole-
cular transphosphorylation of Chk2 on its C-terminal kinase domain (Ahn et
al., 2002; Xu et al., 2002; Lee and Chung, 2001), a modification required for
a full activation of Chk2 toward heterologous substrates. A recent report
indicates that the ATM-dependent phosphorylation of Chk2 cannot occur
freely in the nucleoplasm, but requires a specific DSB-associated adaptor
protein(s) (Lukas et al., 2003). In addition, other checkpoint proteins may
coregulate the physiological velocity and/or timing of Chk2 activation.
These factors include a DSB-interacting protein (53BP1), DNA ends-process-
ing “MRN” nuclease complex (Mre11/Rand50/Nbs1), and its newly identi-
fied binding partner Mdc1 (see text for details). The exact functional
interplay among these factors is yet to be determined; here, we schemati-
cally indicate the reported protein-protein interaction patterns.
B: Ultraviolet light, stalled replication, and some drugs activate ATR, the
major upstream kinase phosphorylating and activating Chk1 (Feijoo et al.,
2001; Heffernan et al., 2002; Liu et al., 2000; Shiloh, 2003; Zhao and Piwnica-
Worms, 2001). The exact DNA intermediates that lead to activation of
human ATR are not known but its recruitment to DNA requires ATRIP, a DNA-
interacting adaptor protein (Cortez et al., 2001). Several recent studies
show that ATM can also phosphorylate Chk1 in cells exposed to IR,
although to a lesser extent compared to the ATR-mediated effect after
other types of DNA damage (Gatei et al., 2003; Sørensen et al., 2003). Both
ATR and ATM target the SQ-rich C terminus of Chk1, including serines 317
and 345, respectively. These phosphorylations may directly lead to Chk1
activation. Optimal activation of Chk1 also requires a cooperative action
of other factors including the multifunctional BRCA1 tumor suppressor
(Yarden et al., 2002), the claspin adaptor molecule (Kumagai and Dunphy,
2000), and the PCNA-like DNA sliding clamp (Rad9/Rad1/Hus1) together
with its loading factor (Rad17) (Weiss et al., 2002; Zou et al., 2002).
A and B: ATX is a new member of the ATM/ATR kinase family, which could
be activated both by UV light and in response to DSB (R. Abraham, person-
al communication). As such, it likely contributes to Chk1 and Chk2 activa-
tion by diverse types of genotoxic stress.
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function manifested as partial radiation-resistant DNA synthesis
after RNAi-mediated downregulation of Chk2 (or Chk1) in other
human cell types (Sørensen et al., 2003; Zhao et al., 2002).
Compared with human cells, the S phase checkpoint defect was
not as obvious in the slowly proliferating primary Chk2−/− mouse
fibroblasts, but it became apparent when these cells were
immortalized (Hirao et al., 2002).
Collectively, these studies supported partly overlapping
roles of Chk1 and Chk2 in multiple checkpoints, revealed the
distinct requirements for Chk1 versus Chk2 for embryonic
development and viability, and underscored the conditional
nature and low penetrance of Chk2 as a tumor suppressor in
mice.
Chk2 variants predisposing to breast and colon cancer
The first evidence that genetic alteration in Chk2 may predis-
pose to cancer was the finding by Bell et al. (1999) of rare
germline mutations in the Chk2 gene in families with Li-
Fraumeni syndrome (LFS). LFS is a familial cancer syndrome
characterized by multiple tumors at young age, with a predomi-
nance of breast cancer and sarcomas, and it is often linked to
germline mutations in the p53 gene. The same Chk2 protein-
truncating mutation (Figure 3A), 1100delC (Bell et al., 1999;
Lee et al., 2001), was also identified in a small subset of LFS
families in Finland (Vahteristo et al., 2001). The fact that p53
was wild-type in all these cases suggested that germline muta-
tions of Chk2 may represent an alternative genetic defect pre-
disposing to LFS.
The recurrent finding of the 1100delC variant (Figure 3) in
LFS prompted two large parallel studies of Chk2 status in
hereditary breast cancer, both concluding that Chk2 1100delC
is a low-penetrance breast cancer susceptibility allele with a
high degree of statistical significance (Vahteristo et al., 2002;
Meijers-Heijboer et al., 2002). Interestingly, Chk2 1100delC
confers no increased cancer risk in breast cancer families with
mutations in the two previously identified breast cancer suscep-
tibility genes, BRCA1 and BRCA2, consistent with the concept
that Chk2 and BRCA1/2 all participate in the DNA damage
response network whose function can be undermined by any of
these mutations. At the molecular level, the 1100delC truncation
eliminates the kinase domain and activity of Chk2 (Wu et al.,
2001). Furthermore, the 1100delC protein is unstable (J. Falck,
personal communication) and the remaining wild-type allele is
often lost in the tumors (Lee et al., 2001), which together results
in a complete loss of Chk2 function and a gross reduction or
lack of the overall Chk2 protein, a phenomenon that facilitates
detection of tumors with Chk2 1100delC by immunohistochem-
istry (Figure 4;Vahteristo et al., 2002). Interestingly, most recent
data indicate that the 1100delC variant is particularly common
in families predisposed to combined breast and colon cancer
(Schutte et al., 2003).
Unlike the 1100delC variant whose carrier frequency of
1.1%–1.4% is similar in normal populations of Western Europe,
North America, and Finland (Vahteristo et al., 2002; Meijers-
Heijboer et al., 2002), the missense variant Chk2 I157T, origi-
nally detected in rare LFS families (Bell et al., 1999; Vahteristo
et al., 2001), is much more common in normal Finnish popula-
tion (at 5%–6%; Allinen et al., 2001; Kilpivaara et al., our unpub-
lished results) than elsewhere (Lee et al., 2001; Schutte et al.,
2003). Recent data from a large Finnish study show that Chk2
I157T is significantly more frequent among unselected cohort of
breast cancer patients, suggesting that this variant of Chk2 may
contribute to breast cancer in the Finnish population (Kilpivaara
et al., our unpublished results). Mechanistically, the I157T may
contribute to tumorigenesis by a dominant-negative effect on
the remaining wild-type Chk2, rather than through loss of func-
tion as the 1100delC variant. Thus, the Chk2 I157T protein is
stable and itself deficient in recognizing its physiological
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Figure 2. Chk1 and Chk2 as mediators of the
checkpoint signaling network
Following their activation, Chk1 and Chk2 phos-
phorylate unique (green and red, respectively)
and overlapping (blue) downstream effectors
that further propagate the checkpoint signal-
ing. Depending on the type of stress, velocity of
DNA damage, and cellular context, this leads
to (1) switch to the stress-induced transcription
program (E2F1, Brca1, p53), (2) direct or indirect
initiation of DNA repair (BRCA1, p53), (3) acute
delay (degradation of Cdc25A) and/or sus-
tained block (Cdc25C, p53, Plk3) of cell cycle
progression, (4) apoptosis (Pml1, p53, E2F1), and
(5) modulation of the chromatin remodeling
pathways (Tlk1/2). The known target sites of
Chk1 (green), Chk2 (red), and both Chk1 and
Chk2 (blue) on the individual substrates are
shown. Some of the Chk1/Chk2 downstream
effectors are classified as protooncogenes (PO)
or tumor suppressors (TS), as indicated.
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substrates p53 (Falck et al., 2001b), Cdc25A (Falck et al.,
2001a), and BRCA1 (Li et al., 2002), and it undermines the
function of wild-type Chk2 when expressed in the same cells,
resulting in checkpoint defects in response to ionizing radiation
(Falck et al., 2001a).
These and other (Ingvarsson et al., 2002; Sodha et al.,
2002) studies document the involvement of Chk2 defects in
breast cancer and colon cancer susceptibility, and indicate dis-
tinct modes of action for different genetic variants of this tumor
suppressor. They furthermore provide pioneering examples of
pinpointing low-penetrance breast cancer predisposing genes,
of which Chk2 likely represents only the tip of the iceberg. Given
their low penetrance, testing for these Chk2 variants alone
would likely have little predictive value for individual patients.
However, it may eventually allow risk assessment for breast
cancer at the population, or even individual level as part of a
broader panel of analogous variants suitable for profiling and
screening, and thereby prove useful for chemoprevention or
lifestyle counseling.
Chk1 and Chk2 abnormalities in sporadic tumors
In contrast to the functionally overlapping Chk2 kinase which
qualifies as a tumor suppressor, cancer-associated defects of
Chk1 are extremely rare, and so far seem limited to carcinomas
of the colon, stomach, and endometrium
(Bertoni et al., 1999; Menoyo et al.,
2001, Vassileva et al., 2002). Frameshift
mutations due to insertion or deletion of
single adenine in the polyadenine tract
of the Chk1 gene have been reported in
colon and endometrial carcinomas with
microsatelite instability (Bertoni et al.,
1999).The resulting truncated Chk1 pro-
teins (Figure 3A) are predicted to be
defective due to the lack of the C-termi-
nal end of the catalytic domain and the
complete loss of the SQ-rich regulatory
domain, yet given their heterozygous
state, the overall functional impact of these mutations in cancer
cells remains uncertain. A shorter isoform of Chk1 mRNA, pre-
dicted to encode a protein which lacks a conserved subdomain
in the catalytic domain of Chk1, has been detected in a subset
of small cell lung carcinomas (Haruki et al., 2000). The deleted
part of the catalytic domain is predicted to be involved in sub-
strate selectivity, and the significance of the predominant
expression of this alternative Chk1 isoform in fetal lung and in
small cell carcinomas, but not in normal adult lung tissue or
other types of lung tumors, remains to be established. Despite
the fact that Chk1 function and its analogy with Chk2 fit a candi-
date tumor suppressor gene, the complete deficiency of Chk1 in
mice results in early embryonic lethality (see above), and it is
yet to be seen whether noncancerous somatic cells lacking
Chk1 are viable. On the other hand, deletion of Chk1 in a p53-
deficient chicken tumor cell line is tolerable (Zachos et al.,
2003), as are the heterozygous truncation mutations of Chk1 in
some human tumors (Bertoni et al., 1999). Thus, it is plausible
that either hypomorphic mutations of Chk1 or Chk1 defects that
occur during progression of cancer at the stage when cancer
cells are less prone to apoptosis (such as those with mutant
p53) may contribute to enhanced genetic instability in some
tumors.
Somatic mutations of Chk2 have been found in small sub-
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Figure 3. Structure of human Chk1 and Chk2
and their aberrations in cancer
A: Structure of human Chk1. Tumor types with
the reported aberrations of Chk1 gene are indi-
cated (bottom). Specific nature and locations
of the majority of Chk1 genetic abnormalities
have not yet been determined. SQ, a
serine/glutamine-rich region with multiple
ATM/ATR/(ATX) phosphorylation sites.
B: Structure of human Chk2. Positions of tumor-
associated mutations are indicated (top)
together with the list of tumor types, where
these mutations were identified (bottom). Red
boxes highlight three mutations associated with
familial cancer; the asterisk indicates the most
frequent 1100delC mutation found both in spo-
radic and familial cancer; this mutation is indi-
cated by its nucleotide, rather than amino acid
position, due to the established designation of
this variant. The I157T mutant (red-framed)
seems to be associated with higher incidence
of sporadic breast cancer in Finland (see text).
SQ/TQ, a regulatory domain containing multi-
ple ATM/(ATX)-recognition sites; FHA, a fork-
head-associated domain required for Chk2
homodimerization and other protein-protein
interactions.
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sets of diverse types of sporadic human malignancies (Figure
3B), including carcinomas of the breast (Sullivan et al., 2002),
lung (Haruki et al., 2000), vulva (Reddy et al., 2002), urinary
bladder (J. Bartkova and P. Guldberg, personal communication),
colon (Bell et al., 1999), and ovary (Miller et al., 2002),
osteosarcomas (Miller et al., 2002), and lymphomas (Hofman et
al., 2001; Hangaishi et al., 2002; Tavor et al., 2001; Tort et al.,
2002). The majority of these mutations are missense or trunca-
tion mutations, clustered in three domains of Chk2: the N-termi-
nal SQ/TQ-rich regulatory domain, the protein-protein
interaction FHA domain, or the C-terminal catalytic domain
(Figure 3B). Some of these Chk2 mutants have been character-
ized functionally at the protein level and found aberrant in sever-
al different ways. Thus, some of the FHA domain (e.g., R145W)
or kinase domain (D311Val, 1100delC) mutants are unstable
proteins, targeted by the proteasome-mediated degradation
machinery, and as a consequence, they are expressed at much
lower levels than the wild-type Chk2 protein (Bartkova et al.,
2001; Lee et al., 2001; Matsuoka et al., 2001). Mutants within
the catalytic domain show decreased or lost kinase activity
(Matsuoka et al., 2001; Wu et al., 2001), while those in the FHA
domain are often defective in recognizing their substrates such
as Cdc25A, p53, or BRCA1 (Falck et al., 2001a, 2001b; Li et al.,
2002), and some of them show a dominant-negative effect
when coexpressed with the wild-type Chk2 (Falck et al., 2001a),
a scenario reminiscent of their heterozygous state in human
tumors. Other mutants (e.g., the “unstable” ones mentioned
above) are unlikely to grossly interfere with the remaining wild-
type Chk2 and may represent “classical” loss-of-function
mutants, an interpretation consistent with the lack of the second
allele due to loss of heterozygosity seen in subsets of such
tumors. The latter tumors show gross reduction or loss of Chk2
staining in immunohistochemical analyses, an approach which
also identified a significant subset of human tumors with low or
undetectable Chk2 protein in the apparent absence of any
mutations in the Chk2 gene (Bartkova et al., 2001; Vahteristo et
al., 2002; Sullivan et al., 2002; Tort et al., 2002). Epigenetic
silencing of gene expression through promoter methylation has
been excluded as a cause of this phenotype (Sullivan et al.,
2002; Tort et al., 2002), and the finding of normal mRNA levels
of Chk2 in such cases suggested potential posttranscriptional
aberrations of Chk2 as a plausible way to downregulate Chk2
levels during oncogenesis.
Apart from Chk2 mutations or protein downregulation, a
constitutive phosphorylation of the activatory threonine 68 of
Chk2 has been found in human cancer cell lines, particularly
those with mutant p53, and in subsets of human primary breast
and colon carcinomas (DiTullio et al., 2002). Such checkpoint
activation in cells without any external DNA damage, and in
tumors untreated by chemotherapy or radiotherapy, raises the
question about the origin of the stimulus that evoked such a
constitutive response of the ATM-Chk2 pathway. Regardless of
the activating insult, this persistent activation of Chk2 likely
increases the selective pressure in human cancers to mutate
p53 (DiTullio et al., 2002), an important aspect of cancer biology
that is also addressed in the next section.
The Chk2-p53 connection
The widely accepted view that Chk2 phosphorylates the N-ter-
minal activation domain of p53 and thereby regulates p53 in
response to DSBs, supported by a large body of evidence
(Chehab et al., 1999, 2000; Shieh et al., 2000; Falck et al.,
2001b; Hirao et al., 2000, 2002; Takai et al., 2002; Lukas et al.,
2003), has recently been challenged based on the following
arguments. First, the p53-derived peptide containing the Chk2-
targeted phosphorylation sites threonine 18 and serine 20 is a
poor substrate for Chk2, and these sequences do not fit the
consensus Chk2 phosphorylation site found in other Chk2 sub-
strates (O’Neill et al., 2002; Ahn et al., 2003). Second, the elimi-
nation of Chk2 by gene knockout or its downregulation by RNAi
resulted in only partial or no defects in the DNA damage-
induced phosphorylation and stabilization of p53 (Hirao et al.,
2000, 2002; Takai et al., 2002; Jallepalli et al., 2003; Ahn et al.,
2003), which seemed surprising given the postulated key role of
Chk2-mediated serine 20 phosphorylation in regulation of p53
protein turnover. Third, the occurrence of concomitant muta-
tions of p53 and Chk2 in the same tumor contrasts with mutual-
ly exclusive cancer-associated aberrations of some other
functionally linked genes such as p53 and mdm2, and the for-
mer phenomenon has been interpreted as evidence against the
p53 and Chk2 tumor suppressors operating in the same linear
pathway.
However, most recent biochemical, genetic, and functional
analyses of the Chk2-p53 link reconcile most of these apparent
discrepancies and further support the physiological role of Chk2
as a p53 kinase. Thus, unlike Cdc25A or Cdc25C which contain
the Chk2 consensus sites and can serve as good substrates
even in the form of short peptides, activation of Chk2 as kinase
toward threonine 18 and serine 20 of p53 requires allosteric
changes in Chk2 induced by its interaction with sequences in
the core domain of native full-length p53. This novel and unex-
pected mode of Chk2 regulation as a p53 kinase (T. Hupp, per-
sonal communication) reveals existence of two classes of Chk2
substrates and highlights the emerging concept of protein
kinase docking sites as modulators of substrate specificity. The
phosphorylations at Thr18 or Ser20 attenuate MDM2 interaction
with p53 and create a p300 phospho-consensus binding site,
thereby operating as a molecular switch to convert p53 from a
protein that binds its negative regulator MDM2 to a p300 bind-
ing protein subject to enhanced acetylation by p300 (Shieh et
al., 2000; Schon et al., 2002; Dornan et al., 2003). Thus, Chk2
contributes to regulation of p53 stabilization, yet regulates also
the activation of p53, consistent with the pronounced defect of
p53-dependent transcription in Chk2-deficient mouse cells
(Hirao et al., 2000; Takai et al., 2002) and with the rate-limiting
effects of Chk2 on p53 function in human cells (Chehab et al.,
2000; Falck et al., 2001b; Lukas et al., 2003).
Finally, when considering the selective advantages of cancer
cells with single versus dual defects in the Chk2-p53 pathway, it is
essential to realize that most types of cellular stresses (including
some types of DNA damage) that activate p53 do not activate
Chk2 and therefore can signal to p53 normally even in the
absence of Chk2. And vice versa, Chk2 has several other impor-
tant functions apart from targeting p53 (Figure 2); so in the
absence of either Chk2 or p53, the other protein remains
engaged in multiple checkpoint pathways. In addition, even in
response to DSBs, the role of Chk2 as a p53 kinase is likely part-
ly redundant, and at least the functionally overlapping kinase
Chk1 has been found to undergo rapid activation in Chk2-defi-
cient cells (Takai et al., 2002), consistent with a potential compen-
satory role in the absence of Chk2. Given these biological
features of the Chk2-p53 interplay, it is understandable why Chk2
deletion or mutation does not recapitulate the effects of p53 inac-
tivation in human cancer cells. Thus, despite the fact that Chk2
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and p53 do operate in a linear pathway in response to DSBs, can-
cer cells defective in Chk2 are still under selective pressure to
inactivate p53, a concept consistent with the observed concomi-
tant mutations of p53 and Chk2 in some tumors (Bell et al., 1999;
Falck et al., 2001b; Sullivan et al., 2002; Reddy et al., 2002).
Checkpoint kinases as potential therapeutic targets
The common, possibly universal occurrence of checkpoint
defects distinguishes cancer cells from normal cells, thereby
providing a potential target for therapeutic intervention. One
strategy, tested with a moderately positive outcome in various
cancer models in cell culture, has been to inhibit the checkpoint
signaling to enhance the impact of concomitant treatment with
DNA-damaging drugs or radiation (reviewed in Bartek et al.,
2001; Dixon and Norbury, 2002). The rationale behind such
selective sensitization of cancer cells is that, unlike normal cells
with a full arsenal of checkpoint responses, tumors defective in
some checkpoint(s) could be deprived of their remaining check-
point pathway(s), and consequently driven into cell death due to
accumulation of excessive DNA damage. So far, the major sce-
nario explored for such experiments has been to target p53-
deficient cancers that lack the G1 checkpoint and to inhibit the
checkpoint kinases known to participate in the G2 checkpoint,
such as ATM/ATR (e.g., by caffeine) or Chk1 (by chemical
inhibitors such as UCN-01). Despite the fact that the applicabili-
ty of UCN-01 in the clinic seems limited due to sequestration of
the inhibitor by plasma proteins (reviewed in Dixon and Norbury,
2002), new small molecule inhibitors of Chk1, possibly even
more specific than UCN-01, are emerging (Sørensen et al.,
2003), and this strategy to sensitize tumors is clearly worth
exploring further.
A conceptually distinct approach is to selectively enhance
cell death in cancer cells that often express higher than normal
levels of the proapoptotic E2F1 transcription factor, itself a sub-
strate of Chk2 (Stevens et al., 2003; see Figure 2). The first
study following this strategy, based on tumor-selective
suprathreshold stabilization of E2F1 by β-lapachone, produced
encouraging results (Li et al., 2003), and clinical trials along this
route should follow. Given the wide range of genetic defects in
individual tumors, exploring alternative strategies to modulate
checkpoint responses in cancer therapy is clearly warranted,
and such interference may eventually require tailor-made deci-
sions based on profiling of each tumor for defects in the relevant
pathways.
Finally, while most experiments in this direction, as well as
the initial clinical trials using UCN-01, target Chk1, the intriguing
phenotypes of Chk2-deficient mice may inspire analogous
attempts with chemical inhibitors of Chk2.Thus, given the resis-
tance of multiple cell types lacking Chk2 to radiation-induced
apoptosis (Hirao et al., 2002; Takai et al., 2002), perhaps chem-
ical inhibition of Chk2 during radiation might protect sensitive
tissues such as lymphocytes or intestinal epithelium from the
side effects of radiotherapy or drugs that cause DSBs. The
critical issue here would be to identify suitable inhibitors of Chk2
and test whether this strategy could be applied without increas-
ing the incidence of tumors.
Emerging roles: Chk1 a “workhorse,” Chk2 an “amplifier”
of checkpoint responses
Considering their overlapping substrate specificities on the one
hand and differential requirements for embryogenesis and via-
bility and different roles in oncogenesis on the other, simple
models of redundant or parallel functions performed by Chk1
and Chk2 in responses to genotoxic stress seem very unlikely.
Instead, their emerging biological mission is one of mutual com-
plementation and intimate cooperation, a partnership where
Chk1 operates as a workhorse, while Chk2 contributes deci-
sively yet only under circumstances that cause DSBs. This con-
cept can perhaps best be illustrated by the involvement of Chk1
and Chk2 in regulation of the protooncogenic human Cdc25A
phosphatase in response to ionizing radiation, a mechanism
which requires a series of phosphorylation events performed
jointly in cooperation by Chk1 and Chk2 (Sørensen et al., 2003).
Chk1 alone targets the same four residues of Cdc25A even in
normal unperturbed cell cycles (Sørensen et al., 2003), and this
function of Chk1 is required to regulate the physiological
turnover of Cdc25A, and thereby normal cell cycle transitions.
This workhorse function of Chk1 is also a prerequisite for the
DNA damage-induced accelerated degradation of Cdc25A
(Zhao et al., 2002; Sørensen et al., 2003), a ubiquitin/protea-
some-mediated process which silences Cdc25A. The resulting
inhibition of the G1/S- and G2/M-promoting cyclin-dependent
kinases leads to promptly deployed cell cycle delays in G1
(Mailand et al., 2000), in S (Falck et al., 2001), as well as in G2
(Mailand et al., 2002) phases of the cell cycle. Conceptually, the
essential role of Chk1 in the maintenance of unperturbed S
phase events shows one example of why Chk1 is an essential
gene which cannot be substituted even by a functionally over-
lapping kinase such as Chk2. Together with the lethal conse-
quences of Chk1 deficiency in mammals, this model could also
explain the paucity of cancer-associated mutations of Chk1.
In contrast, the nonessential Chk2 kinase contributes to the
maintenance of genomic integrity only conditionally, and partly
in a redundant fashion, to some extent replacable by the essen-
R E V I E W
Figure 4. Examples of Chk2 aberrations in
human breast cancer
The breast cancer-associated Chk2 defects
include loss of Chk2 expression (left) and
abnormal activation (right). Sections of
formaldehyde-fixed normal and cancerous tis-
sue were immunostained with antibodies to
total Chk2 (left) and Chk2 phosphorylated by
ATM on threonine 68 (right). e, epthelium; s,
stroma; t, tumor tissue.
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tial workhorse Chk1, and possibly even by other kinases such
as cTAK or Plk3. These features are consistent with Chk2 being
dispensible for embryonic development and viability, and with
the observed low-penetrance tumor suppressor function in both
human and mouse tumorigenesis. In the latter model of Chk2-
deficient mice, such a tumor suppressor role of Chk2 is manifest
mainly under treatment of the mice with external carcinogens,
i.e., under conditions when the otherwise “dormant” tumor sup-
pressor function of this checkpoint amplifier is challenged by the
increased burden of genotoxic stress. To follow the example
quoted above for Chk1, one such situation demanding Chk2
function is the generation of DSBs in S phase, a particularly vul-
nerable period of the cell cycle, when Chk2 increases the rate of
phosphate exchange on Cdc25A residues targeted by Chk1
(Sørensen et al., 2003), and thereby amplifies the “housekeep-
ing” function of Chk1.
There are still a large number of issues to be addressed
before the current knowledge about Chk1 and Chk2 can be
applied for the benefit of cancer patients. Among the immediate
tasks is the search for additional substrates of these kinases,
better mechanistic understanding of their integration within the
checkpoint network, and a more comprehensive assessment of
the extent and clinical as well as epidemiological significance of
cancer-associated aberrations of Chk2 particularly. Last but not
least, isolation of new small molecule inhibitors of Chk1 and
Chk2 and design and validation of novel strategies of check-
point modulation, combined with the traditional radiation and
chemotherapy modalities, hold promise for improved treatment
of cancer.
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